share_log

Supernus Pharmaceuticals Analyst Ratings

Supernus Pharmaceuticals Analyst Ratings

Supernus 製藥分析師評級
Benzinga ·  2023/10/26 03:37
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/25/2023 79.72% Piper Sandler $43 → $42 Maintains Overweight
05/10/2023 96.83% Piper Sandler $45 → $46 Maintains Overweight
01/23/2023 101.11% Piper Sandler $40 → $47 Maintains Overweight
08/31/2022 62.6% Piper Sandler $33 → $38 Maintains Overweight
04/13/2021 71.16% Jefferies $25 → $40 Upgrades Hold → Buy
06/16/2020 32.65% Piper Sandler $25 → $31 Upgrades Neutral → Overweight
06/15/2020 2.7% Jefferies → $24 Reinstates → Hold
04/16/2020 2.7% Stifel $25 → $24 Maintains Hold
11/07/2019 -1.58% Stifel $55 → $23 Downgrades Buy → Hold
11/06/2019 Jefferies Downgrades Buy → Hold
12/17/2018 169.58% Mizuho $61 → $63 Maintains Buy
11/12/2018 178.13% B. Riley Securities $68 → $65 Maintains Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年10月25日 79.72% 派珀·桑德勒 $43→$42 維護 超重
2023年05月10日 96.83% 派珀·桑德勒 $45→$46 維護 超重
2023年1月23日 101.11% 派珀·桑德勒 $40→$47 維護 超重
2022年08月31日 62.6% 派珀·桑德勒 $33→$38 維護 超重
04/13/2021 71.16% 傑富瑞 $25→$40 升級 持有→購買
06/16/2020 32.65% 派珀·桑德勒 $25→$31 升級 中性→超重
2020/06/15 2.7% 傑富瑞 →$24 恢復 →保留
04/16/2020 2.7% Stifel $25→$24 維護 保持
2019/07/11 -1.58% Stifel $55→$23 評級下調 購買→Hold
2019/06/11 - 傑富瑞 評級下調 購買→Hold
2018年12月17日 169.58% 瑞穗 $61→$63 維護
2018年11月12日 178.13% B.萊利證券 $68→$65 維護

What is the target price for Supernus Pharmaceuticals (SUPN)?

Supernus PharmPharmticals(SUPN)的目標價是多少?

The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on October 25, 2023. The analyst firm set a price target for $42.00 expecting SUPN to rise to within 12 months (a possible 79.72% upside). 3 analyst firms have reported ratings in the last year.

派珀·桑德勒於2023年10月25日報道了Supernus製藥公司(納斯達克代碼:SUPN)的最新目標價。這家分析公司將目標價定為42.00美元,預計SUPN將在12個月內上漲(可能上漲79.72%)。3家分析公司在過去一年公佈了評級。

What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?

Supernus PharmPharmticals(SUPN)的最新分析師評級是多少?

The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.

分析師對Supernus PharmPharmticals(納斯達克代碼:SUPN)的最新評級由Piper Sandler提供,Supernus PharmPharmticals維持其增持評級。

When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?

Supernus PharmPharmticals(SUPN)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on October 25, 2023 so you should expect the next rating to be made available sometime around October 25, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與Supernus製藥公司的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Supernus製藥的上一次評級是在2023年10月25日提交的,所以你應該預計下一次評級將在2024年10月25日左右的某個時候公佈。

Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?

分析師對Supernus PharmPharmticals(SUPN)的評級正確嗎?

While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $43.00 to $42.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $23.37, which is out of the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的Supernus製藥(SUPN)評級維持不變,目標價在43.00美元至42.00美元之間。Supernus製藥(SUPN)目前的交易價格為23.37美元,超出了分析師的預測區間。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論